VX-765: Selective Oral Caspase-1 Inhibitor for Inflammation Research

Executive Summary: VX-765 (A8238) is an orally available pro-drug that selectively inhibits caspase-1, a key mediator of IL-1β and IL-18 maturation in canonical inflammasome pathways (Taabazuing et al., 2023). It is metabolized in vivo to VRT-043198, its active form, and demonstrates selectivity by sparing cytokines such as IL-6, IL-8, TNFα, and IL-α. VX-765 reduces inflammation and pyroptosis in preclinical models of arthritis, skin inflammation, and HIV-associated CD4 T-cell death (APExBIO). The compound is insoluble in water but highly soluble in DMSO (≥313 mg/mL) and stable when stored desiccated at -20°C. It enables precise, non-immunosuppressive modulation of the caspase-1 signaling pathway, making it a benchmark tool for translational and mechanistic studies (Related Review).

Biological Rationale

Caspase-1, also known as interleukin-1 converting enzyme (ICE), is a cysteine protease that processes inactive pro-IL-1β and pro-IL-18 into their active, secreted forms in response to inflammasome activation (Taabazuing et al., 2023). This proteolytic processing is pivotal for innate immune defense and the propagation of inflammatory responses. Dysregulation of caspase-1 activity has been implicated in autoinflammatory diseases, including rheumatoid arthritis and certain neuroinflammatory conditions. The canonical inflammasome, assembled upon recognition of pathogen- or danger-associated molecular patterns by cytosolic PRRs (pattern recognition receptors), recruits pro-caspase-1 via the ASC adaptor, leading to its activation and subsequent cytokine cleavage (VX-765 in BBB repair). Selective inhibition of caspase-1 is therefore critical for dissecting inflammatory signaling without broad immunosuppression or off-target cytokine effects.

Mechanism of Action of VX-765

VX-765 is an orally absorbed, cell-permeable pro-drug that is rapidly converted by esterases in vivo to VRT-043198, the active inhibitor of caspase-1 (APExBIO). VRT-043198 binds to the active site of caspase-1, preventing cleavage of pro-IL-1β and pro-IL-18. This results in decreased secretion of mature IL-1β and IL-18, with no significant effect on other key cytokines such as IL-6, IL-8, TNFα, or IL-α. VX-765 does not inhibit non-canonical inflammasome caspases (caspases-4, -5, or -11), nor does it impact NLRP3-independent inflammatory pathways (Taabazuing et al., 2023). The selectivity of VX-765 for the ICE/caspase-1 sub-family enables targeted modulation of canonical inflammasome-mediated events, such as pyroptosis and cytokine release in macrophages.

Evidence & Benchmarks

• VX-765 selectively inhibits caspase-1-mediated cleavage of pro-IL-1β and pro-IL-18, with minimal activity on non-canonical caspases-4/5/11 (Taabazuing et al., 2023).
• In collagen-induced arthritis mouse models, oral VX-765 significantly reduces joint inflammation and serum IL-1β levels (dose-dependent, p<0.01) (APExBIO).
• Topical administration of VX-765 in murine skin inflammation decreases local cytokine release and histological markers of inflammation (Related Review).
• VX-765 prevents CD4 T-cell pyroptotic death in ex vivo HIV-infected lymphoid tissue models, demonstrating dose-dependent protection and reduction of caspase-1 activity (IC50 < 5 μM in tissue culture, 37°C, pH 7.5) (Extended Mechanistic Study).
• In buffer-based enzyme assays at pH 7.5 with 1 mM DTT, VX-765 shows high inhibitory potency (Ki < 10 nM for caspase-1) and stable activity for >2 hours at 25°C (APExBIO).

This article extends prior reviews by synthesizing recent mechanistic findings and providing updated experimental parameters for VX-765 use, in contrast to previous overviews that focus mainly on clinical perspectives.

Applications, Limits & Misconceptions

VX-765 is used extensively in preclinical models of inflammatory and autoimmune conditions, including rheumatoid arthritis, skin inflammation, and HIV-associated immune cell death (APExBIO). Its selectivity for caspase-1 allows for dissection of canonical inflammasome-mediated pyroptosis and cytokine secretion. VX-765 is under active investigation for therapeutic use in epilepsy and other neuroinflammatory disorders, although it is not currently approved for clinical use in humans. The compound's oral bioavailability and high solubility in DMSO facilitate both in vivo and in vitro studies.

Common Pitfalls or Misconceptions

• VX-765 does not inhibit non-canonical caspase-4/5/11 or prevent GSDMD-mediated pyroptosis in pathways independent of caspase-1 (Taabazuing et al., 2023).
• It does not broadly suppress the immune system or affect cytokines such as IL-6, IL-8, or TNFα (Benchmark Article).
• VX-765 is insoluble in water; improper solvent use (e.g., aqueous buffers) leads to precipitation and loss of activity (APExBIO).
• Prolonged storage of reconstituted solutions at room temperature degrades compound potency; solutions should be freshly prepared (APExBIO).
• VX-765 is not a pan-caspase inhibitor; it shows high selectivity for ICE/caspase-1 sub-family only.

Workflow Integration & Parameters

For in vitro enzyme inhibition assays, dissolve VX-765 in DMSO (≥313 mg/mL) or ethanol (≥50.5 mg/mL with ultrasonic aid) and dilute into buffer (pH 7.5, 1 mM DTT) for final concentrations. Store powder desiccated at -20°C; use reconstituted solutions immediately or store short-term at -20°C. For cell-based assays, preincubate VX-765 for 15–30 minutes prior to stimulation. In vivo, oral dosing should follow established protocols (e.g., 25–200 mg/kg in rodent studies). Monitor for precipitation in aqueous solutions and avoid prolonged storage. For advanced mechanistic insights and translational benchmarks, see this mechanistic study, which provides additional context on pyroptosis and mitochondrial apoptosis not addressed here.

Conclusion & Outlook

VX-765, provided by APExBIO, remains a gold-standard selective oral inhibitor for caspase-1 in inflammation research. Its precise mechanism, robust selectivity, and validated performance in preclinical models position it as an essential tool for dissecting canonical inflammasome pathways. Future research will clarify its role in translational medicine and further refine its integration into complex disease models. This article synthesizes fundamental facts, recent mechanistic advances, and best practices for researchers seeking to modulate the caspase-1 pathway with high specificity and reliability.